Infinity Pharmaceuticals Inc (INFI) Stock
INFI is no longer traded. Infinity Pharmaceuticals was delisted from the Nasdaq in November 2023.
Prices on this page are historical; the last trade was November 30, 2023 at $0.00.
Infinity Pharmaceuticals stock price history
INFI final trading statistics
- Final close
- $0.00
- Final trading day
- Nov 30, 2023
- Market cap at delisting
- $726.1K
- Shares outstanding
- 90.76M
- Final 52-week range
- $0.00 – $0.77
- Avg. volume (final 3 mo.)
- 830,497
- All-time high (split-adj.)
- $100.00 · Sep 2000
- All-time low (split-adj.)
- $0.00 · Nov 2023
- Return since IPO
- -100.0%
- Beta
- 1.38
- Book value / share
- -$0.41
- Price / book
- -0.01
Infinity Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $2.59M | -$43.3M | -$0.50 |
| FY2021 | $1.86M | -$45.4M | -$0.53 |
| FY2020 | $1.72M | -$42.9M | -$0.67 |
| FY2019 | $3.05M | -$47.1M | -$0.82 |
| FY2018 | $22.15M | -$11.3M | -$0.21 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Infinity Pharmaceuticals Inc
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Infinity Pharmaceuticals stock FAQ
What happened to Infinity Pharmaceuticals stock?
Infinity Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $0.00 on November 30, 2023.
Is INFI stock still trading?
No. INFI was delisted from the Nasdaq in November 2023 and no longer trades on a U.S. exchange.
What was the last price of INFI stock?
INFI closed at $0.00 on its final trading day, November 30, 2023, for a market value of about $726.1K.
What were Infinity Pharmaceuticals's revenue and earnings in its last full fiscal year?
Infinity Pharmaceuticals reported revenue of $2.59M and net income of -$43.3M in fiscal 2022, its last full year as a public company.
When did Infinity Pharmaceuticals go public?
Infinity Pharmaceuticals Inc stock began trading on July 28, 2000.